Burning Rock Biotech (LSE:BNR) ROE % Adjusted to Book Value : -54.60% (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Burning Rock Biotech ROE % Adjusted to Book Value?

Burning Rock Biotech's ROE % for the quarter that ended in Sep. 2024 was -21.84%. Burning Rock Biotech's PB Ratio for the quarter that ended in Sep. 2024 was 0.40. Burning Rock Biotech's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -54.60%.

Burning Rock Biotech ROE % Adjusted to Book Value Historical Data

The historical data trend for Burning Rock Biotech's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burning Rock Biotech ROE % Adjusted to Book Value Chart

Burning Rock Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-91.62

Burning Rock Biotech Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-77.26	-110.23	-75.79	-78.15	-54.60

Competitive Comparison of Burning Rock Biotech's ROE % Adjusted to Book Value

For the Diagnostics & Research subindustry, Burning Rock Biotech's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Burning Rock Biotech's ROE % Adjusted to Book Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Burning Rock Biotech's ROE % Adjusted to Book Value falls into.

Burning Rock Biotech ROE % Adjusted to Book Value Calculation

Burning Rock Biotech's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-66.88%	/	0.73
	=	-91.62%

Burning Rock Biotech's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-21.84%	/	0.40
	=	-54.60%

Burning Rock Biotech ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Burning Rock Biotech's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Burning Rock Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Burning Rock Biotech Ltd (LSE:BNR) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

BNR:USA 6BU0:Germany

Address

No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005

Website

https://www.brbiotech.com

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.